RedHill’s RHB-102 Targets Major GLP-1 Market Challenge: Phase 2 Study Planned for GI Side Effects

RHB-102 Advances as Potential Solution to GI Side Effects Limiting GLP-1 Therapy Adoption

RedHill Biopharma (NASDAQ: RDHL) is taking aim at one of the biggest hurdles facing the booming GLP-1 therapy market: gastrointestinal (GI) side effects. With more than 2% of Americans currently prescribed GLP-1 receptor agonists and up to 50% of patients reportedly discontinuing treatment within three months, the high rate of nausea, vomiting, and diarrhea presents a significant challenge for both patients and drugmakers. Analysts predict that persistent GI intolerance could knock up to $35 billion off the market's growth by 2030.

Phase 2 Study to Assess RHB-102 for GLP-1/GIP-Induced GI Symptoms

RHB-102, RedHill's proprietary, extended-release oral ondansetron formulation, has just taken a key step forward, with a Phase 2 proof-of-concept study now designed and targeted to begin this year. The company aims to show that a once-daily, bimodal-release antiemetic can reduce the #1 reason for early GLP-1 therapy discontinuation—GI discomfort—helping more patients maintain optimal dosing. This progress sets RHB-102 up as a unique candidate being developed via the accelerated FDA 505(b)(2) pathway, with expanded patent coverage underway.

Robust Clinical Support Across Multiple GI Indications

Unlike some experimental therapies, RHB-102’s safety profile is de-risked by decades of ondansetron use—over 22 million annual ER prescriptions in the U.S. It has already met primary endpoints in published U.S. Phase 3 and Phase 2 studies for gastroenteritis/gastritis and IBS-D, and demonstrated positive pharmacokinetic results in an oncology support setting. As a result, RHB-102 may soon be the first oral, 24-hour extended-release ondansetron therapy positioned for chemotherapy- and radiotherapy-induced nausea and vomiting, as well as post-operative cases.

RHB-102’s Potential Impact on GLP-1 Therapy Persistence

If successful, RHB-102 could address a root cause of patient drop-off during the critical first months of GLP-1/GIP therapy. According to Dr. Terry Plasse, RedHill’s Medical Director, the goal is to help patients get past the “danger zone” where GI side effects are most acute, allowing greater persistence with GLP-1 treatments and unlocking their full therapeutic potential.

Key Takeaway: RHB-102 Poised as Strategic Lever in the Competitive GLP-1 Arena

RedHill is positioning RHB-102 as both a safety net for patients struggling with GI side effects and a strategic asset for biopharma partners looking to reduce costly drop-offs in GLP-1 therapy adherence. While further study results are awaited, the scale of the unmet need—and the clinical foundation supporting RHB-102—make it a development to watch for anyone interested in the future of diabetes, obesity, and GI care.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI